U.S. Antisense And RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, Antisense RNA), By Application (Ocular, Genetic), By Route Of Administration, And Segment) - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2033

U.S. Antisense And RNAi Therapeutics Market Growth Factors

The U.S. antisense and RNAi therapeutics market size was valued at USD 3.11 billion in 2023 and is projected to surpass around USD 17.87 billion by 2033, registering a CAGR of 19.11% over the forecast period of 2024 to 2033.

U.S. Antisense And RNAi Therapeutics Market Key Takeaways

• The largest market share in 2023 was held by the intravenous injections segment,
• The subcutaneous injection segment is anticipated to expand at the fastest CAGR from 2024 to 2033.
• Based on technology, antisense technology dominated this market with the highest share of 70.19% in 2023.
• The RNA interference (RNAi) segment is expected to grow fastest from 2024 to 2033.
• Based on applications, the neurodegenerative disorder segment held the largest share with 70.25% in 2023.
• The genetic disorders segment is projected to grow at a CAGR of 20.1% from 2024 to 2033

U.S. Antisense And RNAi Therapeutics Market Growth Factors

Multidisciplinary applications of antisense technology in a variety of disorders, rising cancer prevalence, and favorable government initiatives and funding fuel industry expansion. Furthermore, increased collaborations among leading businesses to develop RNAi treatments are expected to accelerate growth.  In 2023, the United States accounted for 63.0% of the worldwide antisense and RNAi therapies market. Increased government efforts and financing for R&D activities promote the expansion of biopharmaceutical enterprises. These government efforts aim to raise awareness and spur the production of antisense and RNAi treatments in the marketplace. Furthermore, the availability of external grants encourages the commercialization of novel cures as well as the development of drugs to reduce the country's disease burden. These developments help to boost market growth potential.

Cancer's high prevalence has made it a leading cause of death in the United States, thereby putting a strain on healthcare. According to data given by the American Cancer Society, there were 1,958,310 new cases of cancer and 609,820 cancer-related deaths in the United States in 2023. RNAi treatments have a major impact on cancer incidence. According to a PubMed article, RNAi treatments are considered an emerging approach for cancer treatment. RNAi-based treatments target cancer stem cells and hence prevent the normal to cancer cell transition, indicating their relevance in cancer cure. This property of RNAi therapies is projected to increase demand in the industry.

Furthermore, various companies and research institutes are collaborating and performing clinical studies to improve the development of new antisense and RNAi-based therapeutics to meet the market's unmet needs and lower illness burdens, consequently increasing patient numbers. For example, in August 2023, Sermonic revealed the successful findings of RNAi therapies for numerous solid cancers based on Phase I clinical study data.

U.S. Antisense And RNAi Therapeutics Market Report Scope

U.S. Antisense And RNAi Therapeutics Market Trends

• Increasing Prevalence of Genetic Disorders: The rising incidence of genetic disorders, such as Huntington's disease, cystic fibrosis, and Duchenne muscular dystrophy, has boosted the demand for antisense and RNAi therapeutics.
• Advancements in RNA Interference (RNAi) Technology: Continuous advancements in RNAi technology have led to the development of more efficient and specific therapeutics. This has expanded the scope of RNAi-based treatments for various diseases.
• Growing Investment in Research and Development: Pharmaceutical companies and research institutions are increasingly investing in the research and development of antisense and RNAi therapeutics. This investment is driving innovation and the discovery of novel therapeutic targets.
• FDA Approvals and Pipeline Developments: FDA approvals for antisense and RNAi-based drugs have provided validation for these therapies and increased confidence among investors and stakeholders. Additionally, the robust pipeline of drugs in clinical development indicates the potential for future market growth.
• Partnerships and Collaborations: Collaboration between pharmaceutical companies, biotech firms, and academic institutions has accelerated the development and commercialization of antisense and RNAi therapeutics. These partnerships leverage complementary expertise and resources to advance research and bring therapies to market more efficiently.
• Targeted Therapies with Reduced Side Effects: Antisense and RNAi therapeutics offer the potential for highly targeted treatments with reduced side effects compared to traditional small molecule drugs. This makes them attractive options for patients and healthcare providers.
• Expansion Beyond Rare Diseases: While initially focused on rare genetic disorders, the application of antisense and RNAi therapeutics is expanding to a broader range of diseases, including cancer, infectious diseases, and metabolic disorders. This broader applicability is driving market growth and diversification.
• Technological Advancements in Drug Delivery: Innovations in drug delivery systems are improving the efficiency and specificity of antisense and RNAi therapeutics. Enhanced delivery methods are overcoming challenges such as stability, biodistribution, and cellular uptake, further driving market expansion.

U.S. Antisense And RNAi Therapeutics Market by Route of Administration Insights

The largest market share in 2023 was held by the intravenous injections segment, which was attributed to the favorable pharmacokinetics and high bioavailability of this route of administration. Intravenous injections ensure rapid delivery of antisense and RNAi therapeutics throughout the body by avoiding gastrointestinal and liver barriers. IV-administered antisense & RNAi therapeutics offer improved penetration into tumor tissues and allow selective accumulation within tumor microenvironments. Enhancing their efficacy against cancer cells while minimizing systemic toxicity. These trends further elevate the demand for IV injections, supporting the segment’s growth.

The subcutaneous injection segment is anticipated to expand at the fastest CAGR from 2024 to 2033. This is a convenient and pain-free route of administration, offering long-term therapeutic effects. Moreover, this route provides stability, solubility, & tissue-specific targeting of advanced antisense and RNAi therapeutics, such as lipid nanoparticles and polymer-based carriers in patients.

U.S. Antisense And RNAi Therapeutics Market by Technology Insights

Based on technology, antisense technology dominated this market with the highest share of 70.19% in 2023. This technology regulates protein and gene expression, helping treat chronic cardiovascular, respiratory, and neurological diseases. The factors driving the growth include growing healthcare investments and M&A activities performed by key companies. For instance, in 2022, Wave Life Sciences Ltd. partnered with GSK to escalate Wave's PRISM platform by advancing RNA-based modalities. Such initiatives are expected to boost the market growth.

The RNA interference (RNAi) segment is expected to grow fastest from 2024 to 2033. RNAi is a promising technology offering a gene regulation mechanism, enabling the blocking of disease-causing genes. RNAi is becoming increasingly popular as a therapeutic option for different illnesses, including viral infections, cancer, and inflammatory disorders. Additionally, this industry's growth is fueled by government grants and incentives.

U.S. Antisense And RNAi Therapeutics Market by Application Insights

Based on applications, the neurodegenerative disorder segment held the largest share with 70.25% in 2023. This growth can be attributed to high prevalence of neurodegenerative disorders in this country. This includes disorders such as Alzheimer's disease and Parkinson's disease. According to the "National Institute of Environmental Science," approximately 6.2 million US residents are estimated to have Alzheimer's disease in 2022. Furthermore, about a million people have had Parkinson's disease in the U.S. lately. The burden of these disorders can be reduced using Antisense & RNAi therapeutics through targeted approaches. Thus, the wide applications of antisense and RNAi technology in treating neurodegenerative disorders fuel the segment's growth.

The genetic disorders segment is projected to grow at a CAGR of 20.1% from 2024 to 2033 owing to the significance of RNAi therapeutics in genetic disorders cure. RNAi therapy is capable of treating genetic diseases with high efficiency and specificity. With the help of single nucleotide polymorphism, it keeps track of disease-specific genetic variants. Moreover, nucleic acid research advancements and target delivery will likely accelerate the segment's growth over the forecast period.

U.S. Antisense And RNAi Therapeutics Market Recent Developments

• In March 2023, Alnylam Pharmaceuticals, Inc. announced the expansion with Medison Pharma to introduce innovative therapies for patients in international markets, along with the expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia, and Latvia, in addition to Israel. 

U.S. Antisense And RNAi Therapeutics Market Top Key Companies:

• Sarepta Therapeutics, Inc.
• Ionis Pharmaceuticals, Inc.
• Benitec Biopharma, Inc.
• Arbutus Biopharma
• Alnylam Pharmaceuticals, Inc.
• Microsynth AG
• Aragen Bioscience
• Moderna
• Nutcracker Therapeutics
• Deep Genomics

U.S. Antisense And RNAi Therapeutics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Antisense And RNAi Therapeutics market.

By Technology 

• RNA Interference
• Antisense RNA

By Application 

• Ocular
• Cardiometabolic & Renal Disorders
• Neurodegenerative Disorders
• Genetic Disorders

By Route of Administration 

• Intravenous Injections
• Intrathecal Injections
• Subcutaneous Injections